MedHeed is an AI-powered platform for healthcare professionals, designed to accelerate medical research and clinical decision-making. It uses advanced NLP to analyze and synthesize vast amounts of medical literature, clinical trial data, and treatment guidelines, providing users with curated, evidence-based insights in real-time.
Rayyan is an AI-powered platform designed for researchers to accelerate systematic and literature reviews. It streamlines the process with features like automated screening, duplicate detection, and real-time collaboration, saving researchers up to 90% of their screening time. Trusted by over 800,000 users, it supports the entire review lifecycle from data import to final reporting.
MedHeed is an AI-powered platform for healthcare professionals, designed to accelerate medical research and clinical decision-making. It uses advanced NLP to analyze and synthesize vast amounts of medical literature, clinical trial data, and treatment guidelines, providing users with curated, evidence-based insights in real-time.
Rayyan is an AI-powered platform designed for researchers to accelerate systematic and literature reviews. It streamlines the process with features like automated screening, duplicate detection, and real-time collaboration, saving researchers up to 90% of their screening time. Trusted by over 800,000 users, it supports the entire review lifecycle from data import to final reporting.
| Feature | MedHeed | Rayyan |
|---|---|---|
| Primary category | Medical Research | Academic |
| Added | 2025-08-14 | 2025-09-11 |
| Pricing | Freemium | Freemium |
| Official website | medheed.co | rayyan.ai |
| Product type | Website | Website |
| Performance data | ||
| User rating | Not verified | Not verified |
| Comments | 0 | 0 |
| Monthly visits | 3.4K | 1.1M |
| Monthly growth | Not verified | -4% |
| Favorites | 134 | 128 |
| Details | View details | View details |
Compare MedHeed and Rayyan by monthly reach, traffic trend, visit depth, top regions, and acquisition sources.
In the MedHeed vs Rayyan monthly traffic comparison, MedHeed currently shows 3.4K visits and Rayyan shows 1.1M; Rayyan has about 319.1 times the visible traffic of MedHeed, an absolute difference of about 1.1M visits. This reflects visible reach, not feature quality or paid users.
Only Rayyan has complete third-party traffic details; MedHeed uses visits recorded inside ToolMage. These scopes cannot estimate market share directly, and on-site views should not be treated as the product’s total website traffic.
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 32.99% | 359.1K |
| 🇧🇷Brazil | 31.2% | 339.6K |
| 🇬🇧United Kingdom | 20.31% | 221K |
| 🇵🇰Pakistan | 7.75% | 84.3K |
| 🇵🇹Portugal | 7.75% | 84.3K |
| Source type | Percentage | Traffic |
|---|---|---|
| Direct | 80.86% | 880.1K |
| Referral | 14.66% | 159.6K |
| 4.48% | 48.8K |
This in-depth MedHeed vs Rayyan comparison uses only the product records, taxonomy, audience, traffic, and community signals available on this page. MedHeed is primarily listed under “Medical Research”, while Rayyan is primarily listed under “Academic”, so the first decision is whether your actual task matches their recorded scope.
The structured fields currently show these decision-relevant differences: Primary category (MedHeed: Medical Research; Rayyan: Academic); Monthly visits (MedHeed: 3.4K; Rayyan: 1.1M); Favorites (MedHeed: 134; Rayyan: 128); Website (MedHeed: medheed.co; Rayyan: rayyan.ai); Added (MedHeed: 2025-08-14; Rayyan: 2025-09-11). These facts are more useful for selection than brand visibility alone.
In the MedHeed vs Rayyan monthly traffic comparison, MedHeed currently shows 3.4K visits and Rayyan shows 1.1M; Rayyan has about 319.1 times the visible traffic of MedHeed, an absolute difference of about 1.1M visits. This reflects visible reach, not feature quality or paid users.
Only Rayyan has complete third-party traffic details; MedHeed uses visits recorded inside ToolMage. These scopes cannot estimate market share directly, and on-site views should not be treated as the product’s total website traffic.
The current traffic scope is not sufficient for a reliable product ranking. Treat monthly visits as a market-interest signal, then decide using taxonomy, use cases, pricing, and a like-for-like trial rather than reading exposure as product capability.
MedHeed and Rayyan currently overlap in shared categories: Research; shared tags: data analysis, literature review, and medical research. This can place both on the same shortlist, but it does not prove equal implementation, depth, or cost.
MedHeed's unique categories/tags are Medical Research, clinical trials, drug discovery, evidence-based medicine, healthcare AI, and health tech; Rayyan's are Academic, academic, AI screening, collaboration, deduplication, Prisma, research, and scientific writing. These unique fields are the strongest differentiators: validate the product whose recorded scope matches the task instead of following traffic alone.
MedHeed has no verified rating, 0 comments, 134 favorites, and 122 likes；Rayyan has no verified rating, 0 comments, 128 favorites, and 116 likes。
Neither product has enough rating or comment samples for a credible reputation ranking.
Put MedHeed on the priority trial list when the task aligns with “Medical Research” and especially Medical Research, clinical trials, drug discovery, evidence-based medicine, healthcare AI, and health tech. This follows recorded positioning and does not imply unlisted capabilities are absent.
MedHeed also currently records: pricing is freemium, product type is website, 3.4K on-site monthly views, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
Put Rayyan on the priority trial list when the task aligns with “Academic” and especially Academic, academic, AI screening, collaboration, deduplication, and Prisma, or the users include Academic, Data Analyst, Librarian, and Medical Professional. This follows recorded positioning and does not imply unlisted capabilities are absent.
Rayyan also currently records: pricing is freemium, product type is website, 1.1M verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
The available data describes positioning, public visibility, and community signals, but it cannot prove output quality, speed, integration effort, privacy, or long-term cost in your workflow. Before deciding, run the same representative tasks in MedHeed and Rayyan, then record completion time, accuracy, manual corrections, and the real paid threshold. A like-for-like trial turns this comparison into a defensible adoption decision.
